Elecsys® ProGRP

Progastrin-releasing peptide (ProGRP) is a tumor marker with benefits for the management of small-cell lung cancer patients

Elecsys ProGRP

Crucial information for differential ­diagnosis in lung cancer and monitoring of small-cell lung cancer patients

Progastrin-releasing peptide (ProGRP) is a tumor marker with benefits for the management of small-cell lung cancer patients. The assay is used to aid in the differential diagnosis in Lung Cancer and in the management of patients with small cell lung cancer in conjunction with other clinical methods. The results must be interpreted in conjunction with other methods in accordance with standard clinical guidelines.1

Lung cancer is the the most common cancers in the world with 2 millions new cases diagnosed every year.2 The two main histological types of the disease are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It is important to distinguish between these two subtypes as they have different treatments and prognoses. NSCLC (approx. 80 % of cases), when in the early stages, is curable with surgery. SCLC, however, is an aggressively spreading neoplasm of rapid growth that is usually only treatable with chemo and radiotherapy.3

ProGRP a sensitive, specific tumor marker for patients with small cell lung cancer (SCLC) both in limited (LD) and diffuse disease (DD).4 ProGRP is also a tumor marker that can be used to assess response to therapy as well as to monitor recurrence of the disease.5




  • Specific tumor marker for SCLC, which supports differential diagnosis in lung cancer.6
  • Lung cancer biomarkers available on a single automated platform - Elecsys® CEA, Elecsys® CYFRA 21-1, Elecsys® NSE, Elecsys® ProGRP and Elecsys® SCC.
  • Equivalent performance between plasma and serum for flexibility and convenience, thus offering advantages over existing assays.6
Lung cancer differential diagnosis

The 80.1 pg/mL cut-off value is based on the 95 % ­specificity of the NSCLC collective.1

Use of ProGRP

Use of ProGRP for the primary differential diagnosis in lung cancer. The ability of ProGRP to distinguish SCLC from NSCLC was investigated in a study on 1059 patients in 5 centers in Europe and China (206 SCLCs and 853 NSCLCs), and ProGRP levels were correlated with biopsy proven histology.4

Elecsys® ProGRP

  • Assay time

    18 min

  • Sample volume

    30 μL cobas e 411, cobas e 601, cobas e 602
    18 μL cobas e 801 


  • Detection Limit*

    LoD 3pg/mL, LoQ 7 pg/mL cobas e 411, cobas e 601, cobas e 602
    LoD 3pg/mL, LoQ 9 pg/mL cobas e 801 


  • Measuring Range

    3 - 5,000 pg/mL

  • Sample material

    Serum collected using standard sampling tubes or tubes containing separating gel. Li-heparin plasma, K2-EDTA and K3-EDTA plasma.

*LoD = Limit of Detection; LoQ = Limit of Quantitation (≤ 30 % total error).



  1. Elecsys® ProGRP Method Sheet
  2. Globocan 2018 - Cancer Today at https://gco.iarc.fr/today/online-analysis-multi-bars
  3. American Cancer Society - What is Lung Cancer. Available at https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Last access July 2020
  4. Cavalieri C. et al. (2015). Clinical Implications for pro-GRP in Small Cell Lung Cancer.A Single Center Experience. The International Journal of BiologicalMarkers
  5. Hyung-Joo Oh et al. (2015).Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis. 2016 Sep; 8(9): 2530–2537
  6. Korse. C. et al (2015). Multicenter evaluation of a new progastlin-releasing peptide (ProGRP) immunoassay across Europe and China. Clinica Chimica Acta 438. 388-395